HitGen, Inc.

Detailed Description

HitGen Inc. operates a platform for early-stage drug discovery research focusing on DNA encoded chemical libraries (DELs). Its DELs include encoded syntheses for diverse, drug-likesmall molecule, and macrocycle compounds. The company has internal projects in research, with Phase I, PCC generation, and in lead generation stages that focus on oncology, CVD, inflammation/respiratory, metabolism, and ophthalmology therapeutic areas. HitGen Inc. has a drug discovery research collaboration with Gilead Sciences, Galapagos NV, Kymera Therapeutics, Inc., and Morphic Therapeutic to identify potential small molecule leads; a strategic partnership with Oncodesign Société Anonyme for the identification and progression of new chemical entities; and an agreement with Lipigon Pharmaceuticals AB to include a second novel target, as well as a research collaboration agreement with Dorian Therapeutics, Inc. to discover compounds that bind to certain targets that are of interest to Dorian. The company also has a strategic alliance with Cambridge Molecular Technologies Ltd. to introduce DeepDELve 2 – Cambridge Molecular's DEL-specific deep learning system as an addition to HitGen's DEL discovery platform with approximately 1 trillion drug-like small molecules. HitGen Inc. was founded in 2012 and is based in Chengdu, China.